HPS Statin Trial

Heart Protection Study Collaborative Group Writers - MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial - The Lancet - 2002

Brief Summary:

In patients with high risk for CVD, simvastatin is safe and cholesterol lowering is associated with reduction in all-cause mortality and major vascular event risk, as compared to placebo. The benefit of cholesterol lowering was neither limited by a threshold LDL-C level nor dependent on the pretreatment cholesterol level.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/12114036